Center-Authored Papers

Filters: Author is Gleave, Martin  [Clear All Filters]
Journal Article
Lotan TL, Wei W, Ludkovski O, Morais CL, Guedes LB, Jamaspishvili T, Lopez K, Hawley ST, Feng Z, Fazli L et al..  2016.  Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 29(8):904-914. Abstract
Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R et al..  2016.  Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.. Oncotarget. 7(26):40690-40703. Abstract
Chi KN, Higano CS, Blumenstein B, Ferrero J-M, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM et al..  2017.  Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.. The Lancet. Oncology. Abstract
Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS.  2012.  Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer.. The Journal of urology. 188(1):103-9. Abstract
Telesca D, Inoue LYT, Neira M, Etzioni R, Gleave M, Nelson C.  2009.  Differential expression and network inferences through functional data modeling.. Biometrics. 65(3):793-804. Abstract
Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA et al..  2015.  Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.. PloS one. 10(7):e0132343. Abstract
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N et al..  2017.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.. European urology. Abstract
Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M et al..  2013.  A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.. Advances in anatomic pathology. 20(1):39-44. Abstract
Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A et al..  2015.  A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.. The Prostate. Abstract
Lotan TL, Wei W, Morais CL, Hawley ST, Fazli L, Hurtado-Coll A, Troyer D, McKenney JK, Simko J, Carroll PR et al..  2016.  PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.. European urology focus. 2(2):180-188. Abstract